Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
25.40    -0.20 (-0.78%)
Bid:
25.40
Ask:
26.20
Spread: 0.80 (3.15%)
Market Cap: £109.29m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Strategic Update

23 Oct 2015 17:06

RNS Number : 3163D
EKF Diagnostics Holdings PLC
23 October 2015
 

 

EKF Diagnostics Holdings plc("EKF" or the "Company")

 

Strategic Update

 

The Board note the announcement by Jinjing (Group) Co., Ltd. that they do not intend to make an offer for the Company. The Company is no longer in an offer period under the City Code and, accordingly, the requirement to make disclosures under Rule 8 of the City Code has now ceased.

 

As outlined in the Company's conclusion of strategic review announcement of 18 August 2015, as the interest shown in the Company has not led to a realisation event, the Board now intend to invite Mr Ron Zwanziger to become Chairman, with the current Chairman becoming deputy Non-Executive Chairman.

 

Ron Zwanziger has been the founder and Chief Executive Officer of three highly successful medical diagnostic companies. Mr Zwanziger was Chairman, Chief Executive Officer and President of Alere Inc. from its inception in May 2001 until July 2014. Alere is a global diagnostics company with a $4 billion market capitalisation listed on the New York Stock Exchange. Prior to Alere Mr Zwanziger served as Chairman, Chief Executive Officer and President of Inverness Medical Technology, from its inception in 1992 to November 2001, when that company was acquired by Johnson & Johnson. From 1981 to 1991, he was Chairman and Chief Executive Officer of MediSense, a medical device company. Mr Zwanziger served as a director of AMAG Pharmaceuticals, Inc. from November 2006 to December 2011. Finally, Mr Zwanziger is currently Chairman and Chief Executive Officer of Lumira Holdings Ltd.

 

The Company announced on 24 August 2015 that it had received a non-binding preliminary proposal from an unrelated third party of US$115 million to $125 million for the Company's Point-of-Care business (which excludes the Clinical Chemistry and Molecular Diagnostics businesses). This non-binding preliminary proposal has now been withdrawn.

 

David Evans, Chairman of EKF commented:

"Although we had a number of expressions of interest this has not let to a realisation event. We now look forward to working with Mr Zwanziger as Chairman to build on the solid foundations of the EKF business. Mr Zwanziger brings strategic vision, leadership, extensive business and operating experience and an immense knowledge of the industry to our Board."

 

Further disclosure in accordance with Schedule Two paragraph (g) of the AIM Rules will be made in due course.

 

EKF Diagnostics Holdings plc

Tel: 029 2071 0570

David Evans, Executive Chairman

Mob: 07740 084 452

Julian Baines, CEO

Mob: 07788 420 859

Paul Foulger, CFO

Mob: 07710 989 255

 

 

Panmure Gordon (UK) Limited

Tel: 020 7886 2500

Robert Naylor (Corporate Finance)

 

Paul Fincham (Corporate Finance)

 

Karri Vuori (Corporate Finance)

 

 

 

Walbrook PR Limited 

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

    

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBLBDGSGDBGUX
Date   Source Headline
1st Aug 20227:00 amRNSTrading Update
29th Jun 20224:41 pmRNSSecond Price Monitoring Extn
29th Jun 20224:36 pmRNSPrice Monitoring Extension
28th Jun 20223:34 pmRNSHolding(s) in Company
22nd Jun 20224:36 pmRNSPrice Monitoring Extension
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
20th Jun 20227:00 amRNSDistribution of shares in Verici Dx plc
13th Jun 20227:00 amRNSUpdate on strong cash position
9th Jun 20227:00 amRNSLaunch of EKF Link
23rd May 20227:00 amRNSCancellation of Treasury Shares and TVR
18th May 20221:25 pmRNSResult of AGM
18th May 20227:00 amRNSAGM Statement
3rd May 20227:00 amRNSPDMR/Director Dealings & Holding(s) in Company
25th Apr 20227:00 amRNSPosting of Annual Report & Accounts &Notice of AGM
11th Apr 20227:00 amRNSPurchase of Own Shares & Buyback Prog. Completion
8th Apr 20227:00 amRNSPurchase of Own Shares
7th Apr 20227:00 amRNSPurchase of Own Shares
6th Apr 20227:00 amRNSPurchase of Own Shares
5th Apr 20227:00 amRNSPurchase of Own Shares
4th Apr 20227:00 amRNSPurchase of Own Shares
1st Apr 20227:00 amRNSPurchase of Own Shares
31st Mar 20227:00 amRNSPurchase of Own Shares
30th Mar 20227:00 amRNSPurchase of Own Shares
29th Mar 20227:01 amRNSShare Buyback Programme
29th Mar 20227:00 amRNSFinal Results
25th Mar 20224:40 pmRNSSecond Price Monitoring Extn
25th Mar 20224:35 pmRNSPrice Monitoring Extension
18th Mar 20225:13 pmRNSHolding(s) in Company
7th Mar 20227:00 amRNSFurther Investment in Verici Dx plc
3rd Mar 20224:41 pmRNSSecond Price Monitoring Extn
3rd Mar 20224:36 pmRNSPrice Monitoring Extension
3rd Mar 20227:00 amRNSNotice of Results
31st Jan 20227:00 amRNSNon-executive Directorate Change
25th Jan 20227:00 amRNSTrading update
18th Jan 20227:01 amRNSStrategic partnership agreement with Yourgene
23rd Nov 20217:00 amRNSDirectorate Change
8th Nov 20211:01 pmRNSDirector/PDMR Shareholding
25th Oct 20217:00 amRNSDividend confirmation
12th Oct 20217:00 amRNSCompletion of ADL Health Acquisition
5th Oct 20213:00 pmRNSPDMR/ PCA Dealings
5th Oct 20213:00 pmRNSHolding(s) in Company
28th Sep 20217:00 amRNSAcquisition of Advanced Diagnostic Laboratory LLC
14th Sep 20217:00 amRNSHalf-year Report
25th Aug 20217:00 amRNSNotice of Results
21st Jul 20217:00 amRNSTrading Update
16th Jun 20217:00 amRNSChange of Adviser
7th Jun 202110:10 amRNSInvestor Presentations
26th May 20215:48 pmRNSTrellus Health plc: Successful Restricted Offer
20th May 20214:31 pmRNSTrellus Health plc: Confirmation of Issue Price
19th May 202112:58 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.